Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soazig Chevalier

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Diabetes Care|August 6, 2008
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetesJulio Rosenstock, Priscilla Hollander, Soazig Chevalier, et al.
Diabetes, Obesity & Metabolism|August 31, 2018
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimenGeremia B Bolli, Carol Wysham, Miles Fisher, et al.
Therapeutic Innovation & Regulatory Science|August 28, 2021
Historical Benchmarks for Quality Tolerance Limits Parameters in Clinical TrialsMarcin Makowski, Ruma Bhagat, Soazig Chevalier, et al.
Plos One|January 26, 2018
The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3Jean-François Yale, Jeremy Hodson Pettus, Miguel Brito-Sanfiel, et al.
Therapeutic Innovation & Regulatory Science|September 5, 2020
Quality Tolerance Limits: Framework for Successful Implementation in Clinical DevelopmentRuma Bhagat, Lukasz Bojarski, Soazig Chevalier, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trialJosep Tabernero, Eric Van Cutsem, Radek Lakomý, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapyPaul Ruff, David R Ferry, Radek Lakomỳ, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Diabetes Care|August 6, 2008
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetesJulio Rosenstock, Priscilla Hollander, Soazig Chevalier, et al.
Diabetes, Obesity & Metabolism|August 31, 2018
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimenGeremia B Bolli, Carol Wysham, Miles Fisher, et al.
Therapeutic Innovation & Regulatory Science|August 28, 2021
Historical Benchmarks for Quality Tolerance Limits Parameters in Clinical TrialsMarcin Makowski, Ruma Bhagat, Soazig Chevalier, et al.
Plos One|January 26, 2018
The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3Jean-François Yale, Jeremy Hodson Pettus, Miguel Brito-Sanfiel, et al.
Therapeutic Innovation & Regulatory Science|September 5, 2020
Quality Tolerance Limits: Framework for Successful Implementation in Clinical DevelopmentRuma Bhagat, Lukasz Bojarski, Soazig Chevalier, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trialJosep Tabernero, Eric Van Cutsem, Radek Lakomý, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapyPaul Ruff, David R Ferry, Radek Lakomỳ, et al.
Pageof 1